Page 420 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

398 PART IV Specific Malignancies in the Small Animal Patient

27. Jaffe MH, Hosgood G, Taylor HW, et al.: Immunohistochemi- 50. Zemke D, Yamini B, Yuzbasiyan-Gurkan V: Mutations in the jux-
cal and clinical evaluation of p53 in canine cutaneous mast cell tamembrane domain of c-KIT are associated with higher grade
tumors, Vet Pathol 37:40–46, 2000. mast cell tumors in dogs, Vet Pathol 39:529–535, 2002.
VetBooks.ir 28. Ozaki K, Yamagami T, Nomura K, et al.: Mast cell tumors of the 51. Jark PC, Mundin DB, de Carvalho M, et al.: Genomic copy num-
ber variation associated with clinical outcome in canine cutaneous
gastrointestinal tract in 39 dogs, Vet Pathol 39:557–564, 2002.
29. Mayr B, Reifinger M, Brem G, et al.: Cytogenetic, ras, and p53:
mast cell tumors, Res Vet Sci 111:26–30, 2017.
studies in cases of canine neoplasms (hemangiopericytoma, masto- 52. Mochizuki H, Thomas R, Moroff S, et al.: Genomic profiling of
cytoma, histiocytoma, chloroma), J Hered 90:124–128, 1999. canine mast cell tumors identifies DNA copy number aberrations
30. Wu H, Hayashi T, Inoue M: Immunohistochemical expression of associated with KIT mutations and high histological grade, Chro-
p27 and p21 in canine cutaneous mast cell tumors and histiocyto- mosome Res 25:129–143, 2017.
mas, Vet Pathol 41:296–299, 2004. 53. Giantin M, Baratto C, Marconato L, et al.: Transcriptomic analysis
31. Elling H, Ungemach FR: Sexual hormone receptors in canine mast identified up-regulation of a solute carrier transporter and UDP
cell tumour cytosol, J Comp Pathol 92:629–630, 1982. glucuronosyltransferases in dogs with aggressive cutaneous mast
32. Gerritsen RJ, Teske E, Kraus JS, et al.: Multi-agent chemotherapy cell tumours, Vet J 212:36–43, 2016.
for mast cell tumours in the dog, Vet Q 20:28–31, 1998. 54. Giantin M, Granato A, Baratto C, et al.: Global gene expression
33. Da Silva L, Fonseca-Alves CE, Thompson JJ, et al.: Pilot assess- analysis of canine cutaneous mast cell tumor: could molecular pro-
ment of vascular endothelial growth factor receptors and trafficking filing be useful for subtype classification and prognostication? PLoS
pathways in recurrent and metastatic canine subcutaneous mast cell One 9:e95481, 2014.
tumours, Vet Med Sci 3:146–155, 2017. 55. Schlieben P, Meyer A, Weise C, et al.: Differences in the proteome
34. Thompson JJ, Morrison JA, Pearl DL, et al.: Receptor tyrosine of high-grade versus low-grade canine cutaneous mast cell tumours,
kinase expression profiles in canine cutaneous and subcutaneous Vet J 194:210–214, 2012.
mast cell tumors, Vet Pathol 53:545–558, 2016. 56. Fenger JM, Bear MD, Volinia S, et al.: Overexpression of miR-9
35. Galli SJ, Zsebo KM, Geissler EN: The kit ligand, stem cell factor, in mast cells is associated with invasive behavior and spontaneous
Adv Immunol 55:1–95, 1994. metastasis, BMC Cancer 14:84, 2014.
36. Roskoski Jr R: Structure and regulation of Kit protein-tyrosine 57. Bostock DE: The prognosis following surgical removal of mastocy-
kinase—the stem cell factor receptor, Biochem Biophys Res Commun tomas in dogs, J Small Anim Pract 14:27–41, 1973.
338:1307–1315, 2005. 58. Mullins MN, Dernell WS, Withrow SJ, et al.: Evaluation of
37. Roskoski Jr R: Signaling by Kit protein-tyrosine kinase—the prognostic factors associated with outcome in dogs with multiple
stem cell factor receptor, Biochem Biophys Res Commun 337:1–13, cutaneous mast cell tumors treated with surgery with and with-
2005. out adjuvant treatment: 54 cases (1998-2004), J Am Vet Med Assoc
38. Kiupel M, Webster JD, Kaneene JB, et al.: The use of KIT and 228:91–95, 2006.
tryptase expression patterns as prognostic tools for canine cutane- 59. Van Pelt DR, Fowler JD, Leighton FA: Multiple cutaneous mast
ous mast cell tumors, Vet Pathol 41:371–377, 2004. cell tumors in a dog: a case report and brief review, Can Vet J
39. London CA, Kisseberth WC, Galli SJ, et al.: Expression of stem 27:259–263, 1986.
cell factor receptor (c-kit) by the malignant mast cells from spon- 60. Cohen D, Reif SS, Brodey RS: Epidemiological analysis of the most
taneous canine mast cell tumours, J Comp Pathol 115:399–414, prevalent sites and types of canine neoplasia observed in a veteri-
1996. nary hospital, Cancer Res 34:2859–2868, 1974.
40. Morini M, Bettini G, Preziosi R, et al.: C-kit gene product 61. Crowe DT, Goodwin MA, Greene CE: Total laryngectomy for
(CD117) immunoreactivity in canine and feline paraffin sections, laryngeal mast cell tumor in a dog, J Am Anim Hosp Assoc 22:809–
J Histochem Cytochem 52:705–708, 2004. 816, 1986.
41. Reguera MJ, Rabanal RM, Puigdemont A, et al.: Canine mast 62. Iwata N, Ochiai K, Kadosawa T, et al.: Canine extracutaneous
cell tumors express stem cell factor receptor, Am J Dermatopathol mast-cell tumours consisting of connective tissue mast cells, J Comp
22:49–54, 2000. Pathol 123:306–310, 2000.
42. Halsey CHC, Thamm DH, Weishaar KM, et al.: Expression of 63. Patnaik AK, MacEwen EG, Black AP, et al.: Extracutaneous mast-
phosphorylated KIT in canine mast cell tumor, Vet Pathol 54:387– cell tumor in the dog, Vet Pathol 19:608–615, 1982.
394, 2017. 64. Steffey M, Rassnick KM, Porter B, et al.: Ureteral mast cell tumor
43. Downing S, Chien MB, Kass PH, et al.: Prevalence and importance in a dog, J Am Anim Hosp Assoc 40:82–85, 2004.
of internal tandem duplications in exons 11 and 12 of c-kit in mast 65. Moore TW, Bentley RT, Moore SA, et al.: Spinal mast cell tumors
cell tumors of dogs, Am J Vet Res 63:1718–1723, 2002. in dogs: imaging features and clinical outcome of four cases, Vet
44. Jones CL, Grahn RA, Chien MB, et al.: Detection of c-kit muta- Radiol Ultrasound 58:44–52, 2017.
tions in canine mast cell tumors using fluorescent polyacrylamide 66. Davies AP, Hayden DW, Klausner JS, et al.: Noncutaneous sys-
gel electrophoresis, J Vet Diagn Invest 16:95–100, 2004. temic mastocytosis and mast cell leukemia in a dog: case report and
45. Letard S, Yang Y, Hanssens K, et al.: Gain-of-function mutations literature review, J Am An Hosp Assoc 17:361–368, 1981.
in the extracellular domain of KIT are common in canine mast cell 67. Takahashi T, Kadosawa T, Nagase M, et al.: Visceral mast cell
tumors, Mol Cancer Res 6:1137–1145, 2008. tumors in dogs: 10 cases (1982-1997), J Am Vet Med Assoc
46. London CA, Galli SJ, Yuuki T, et al.: Spontaneous canine mast cell 216:222–226, 2000.
tumors express tandem duplications in the proto-oncogene c-kit, 68. O’Keefe DA, Couto CG, Burke-Schwartz C, et al.: Systemic mas-
Exp Hematol 27:689–697, 1999. tocytosis in 16 dogs, J Vet Intern Med 1:75–80, 1987.
47. London CA, Hannah AL, Zadovoskaya R, et al.: Phase I dose- 69. Moirano SJ, Lima SF, Hume KR, et al.: Association of prognos-
escalating study of SU11654, a small molecule receptor tyrosine tic features and treatment on survival time of dogs with systemic
kinase inhibitor, in dogs with spontaneous malignancies, Clin Cancer mastocytosis: a retrospective analysis of 40 dogs, Vet Comp Oncol
Res 9:2755–2768, 2003. 16:E194–E201, 2018.
48. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, et al.: The role of 70. Pizzoni S, Sabattini S, Stefanello D, et al.: Features and prognos-
c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tic impact of distant metastases in 45 dogs with de novo stage IV
tumors, Neoplasia 8:104–111, 2006. cutaneous mast cell tumours: a prospective study, Vet Comp Oncol
49. Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, et al.: Evaluation 16:28–36, 2018.
of prognostic markers for canine mast cell tumors treated with vin- 71. Tams TR, Macy DW: Canine mast cell tumors, Comp Cont Ed
blastine and prednisone, BMC Vet Res 4:32, 2008. Pract Vet 27:259–263, 1981.